Published online Apr 6, 2024. doi: 10.12998/wjcc.v12.i10.1742
Peer-review started: January 19, 2024
First decision: February 5, 2024
Revised: February 26, 2024
Accepted: March 12, 2024
Article in press: March 12, 2024
Published online: April 6, 2024
Processing time: 74 Days and 2.3 Hours
Speech disorders significantly affect individuals' communication abilities and quality of life. Traditional treatments often show variable outcomes and patient compliance issues. The exploration of innovative, non-invasive therapies like transcranial electrical stimulation (TES) is crucial for advancing treatment effectiveness in this field.
This study is motivated by the need to find more effective, patient-friendly treatment options for speech disorders. The potential of TES as a novel intervention, capable of enhancing neurotrophic factors and improving language functions, drives this research.
The primary objective is to assess the impact of TES, alongside conventional speech and psychological therapies, on serum neurofactor levels and language functions in individuals with speech disorders.
A controlled study was conducted with 81 patients, divided into a control group receiving standard therapies and an observation group receiving additional TES. The study evaluated serum levels of various neurofactors and conducted comprehensive assessments of language and motor functions over a 3-wk period.
The observation group demonstrated significantly higher levels of serum neurofactors (ciliary neurotrophic factor, glial cell-derived neurotrophic factor, brain-derived neurotrophic factor, nerve growth factor) and improved scores in language functions (writing, reading comprehension, retelling, fluency) and development quotient, compared to the control group.
TES, in combination with standard therapies, significantly improves neurofactor levels and language functions in patients with speech disorders. This suggests TES as an effective adjunct therapy in the treatment of speech impairments.
The promising results from this study advocate for further research into TES as a treatment modality for speech di